drugset / Trial / NCT01205126

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

NCT01205126

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of Oral Osmotic Therapeutic System (OROS) hydromorphone hydrochloride (HCl) with controlled-release oxycodone HCl in participants with cancer-related pain.

Timeline

Start
2009-12
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 8 mg Oral
Subject Hydromorphone Other / unclassified 16 mg Oral
Subject Hydromorphone Other / unclassified 24 mg Oral
Subject Hydromorphone Other / unclassified 32 mg Oral
Comparator Oxycodone Other / unclassified 10 mg
Comparator Oxycodone Other / unclassified 20 mg
Comparator Oxycodone Other / unclassified 30 mg
Comparator Oxycodone Other / unclassified 40 mg

Indications

No indication recorded.